{
  "symbol": "JNJ",
  "year": 2024,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1769,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.304
  },
  "top_positive": [
    {
      "sent": "Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;\u00a0and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties.",
      "score": 0.9962
    },
    {
      "sent": "Risks related to healthcare market trends and the realization of benefits from the Company's strategic initiatives \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize th\ntrends and the realization of benefits from the Company's strategic initiatives \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; \u2022 The Company\u2019s ability to realize the anticipated benefits from the separation of Kenvue Inc.",
      "score": 0.9825
    },
    {
      "sent": "Cash flow from operations of $9.3\u00a0billion was the result of: (Dollars In Billions) $ 7.9 Net earnings 2.1 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, and asset write-downs partially offset by the net gain on sale of assets/businesses and the deferred tax provision (1.9) an increase in accounts receivable and inventories 0.4 an increase in accounts payable and accrued liabilities 3.7 a decrease in other current and non-current assets (3.1) a decrease in other current and non-current liabilities 0.2 Other and rounding $ 9.3 Net cash flows from operations Cash flow used by investing activities of $14.2 billion was primarily from: (Dollars In Billions) $ (1.8) additions to property, plant and equipment 0.6 proceeds from the disposal of assets/businesses, net (14.8) acquisitions, net of cash acquired 0.5 net sales of investments 1.4 credit support agreements activity, net (0.1) Other (primarily capitalized licenses and milestones) $ (14.2) Net cash used by investing activities 56 Table of Contents Cash flow from financing activities of $8.1 billion was primarily from: (Dollars In Billions) $ (5.9) dividends to shareholders (1.6) repurchase of common stock 15.9 net proceeds from short and long term debt 0.3 proceeds from stock options exercised/employee withholding tax on stock awards, net 0.3 credit support agreements activity, net (1.0) Settlement of convertible debt acquired from Shockwave 0.1 Other and rounding $ 8.1 Net cash from financing activities The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper.",
      "score": 0.9723
    }
  ],
  "top_negative": [
    {
      "sent": "Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.",
      "score": -0.9531
    },
    {
      "sent": "Russia-Ukraine war Although the long-term implications of Russia\u2019s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal second quarter of 2024, including accounts receivable or inventory reserves, was not material.",
      "score": -0.8271
    },
    {
      "sent": "As of June\u00a030, 2024, the Company had cash, cash equivalents and marketable securities of approximately $25.5 billion and had approximately $41.5 billion of notes payable and long-term debt for a net debt position of $16.0 billion as compared to the prior year fiscal second quarter net debt position of $17.1 billion (which included cash of $1.2 billion and debt of $8.4 billion related to Kenvue).",
      "score": -0.7783
    }
  ],
  "forward_snippets": [
    "Further legislation, guidance and regulations that may be issued in fiscal 2024, as well as other business events, may impact this estimate.",
    "In April 2024, Janssen appealed the district\nguidance and regulations that may be issued in fiscal 2024, as well as other business events, may impact this estimate."
  ],
  "curated_text": "Symbol: JNJ. Year: 2024. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;\u00a0and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties. Risks related to healthcare market trends and the realization of benefits from the Company's strategic initiatives \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize th\ntrends and the realization of benefits from the Company's strategic initiatives \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; \u2022 The Company\u2019s ability to realize the anticipated benefits from the separation of Kenvue Inc. Cash flow from operations of $9.3\u00a0billion was the result of: (Dollars In Billions) $ 7.9 Net earnings 2.1 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, and asset write-downs partially offset by the net gain on sale of assets/businesses and the deferred tax provision (1.9) an increase in accounts receivable and inventories 0.4 an increase in accounts payable and accrued liabilities 3.7 a decrease in other current and non-current assets (3.1) a decrease in other current and non-current liabilities 0.2 Other and rounding $ 9.3 Net cash flows from operations Cash flow used by investing activities of $14.2 billion was primarily from: (Dollars In Billions) $ (1.8) additions to property, plant and equipment 0.6 proceeds from the disposal of assets/businesses, net (14.8) acquisitions, net of cash acquired 0.5 net sales of investments 1.4 credit support agreements activity, net (0.1) Other (primarily capitalized licenses and milestones) $ (14.2) Net cash used by investing activities 56 Table of Contents Cash flow from financing activities of $8.1 billion was primarily from: (Dollars In Billions) $ (5.9) dividends to shareholders (1.6) repurchase of common stock 15.9 net proceeds from short and long term debt 0.3 proceeds from stock options exercised/employee withholding tax on stock awards, net 0.3 credit support agreements activity, net (1.0) Settlement of convertible debt acquired from Shockwave 0.1 Other and rounding $ 8.1 Net cash from financing activities The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper. Top negative sentences: Risks related to economic conditions, financial markets and operating internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal\u00a0systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; \u2022 The impact of global or economic changes or events, including global tensions and war; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets. Russia-Ukraine war Although the long-term implications of Russia\u2019s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal second quarter of 2024, including accounts receivable or inventory reserves, was not material. As of June\u00a030, 2024, the Company had cash, cash equivalents and marketable securities of approximately $25.5 billion and had approximately $41.5 billion of notes payable and long-term debt for a net debt position of $16.0 billion as compared to the prior year fiscal second quarter net debt position of $17.1 billion (which included cash of $1.2 billion and debt of $8.4 billion related to Kenvue). Forward-looking snippets: Further legislation, guidance and regulations that may be issued in fiscal 2024, as well as other business events, may impact this estimate. In April 2024, Janssen appealed the district\nguidance and regulations that may be issued in fiscal 2024, as well as other business events, may impact this estimate."
}